Experimental combo targets Hard-to-Treat tumors
NCT ID NCT03444714
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This early-phase study tested a new drug called RiMO-301 given together with radiation in 32 people with advanced tumors that could not be cured by standard treatments. The drug was injected directly into the tumor to see what dose is safe and tolerable. The goal was to find the best dose and check if the combination helps shrink tumors or ease symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.